Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma

Glioblastoma multiforme (GBM) is a highly heterogeneous and aggressive brain tumor with a dismal prognosis. Development of resistance towards cytostatic drugs like the GBM standard drug temozolomide is a severe problem in GBM treatment. One potential source of GBM relapse could be so called cancer s...

Descripción completa

Detalles Bibliográficos
Autores principales: William, Doreen, Walther, Madlin, Schneider, Björn, Linnebacher, Michael, Classen, Carl Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774812/
https://www.ncbi.nlm.nih.gov/pubmed/29352318
http://dx.doi.org/10.1371/journal.pone.0191511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774812/
https://www.ncbi.nlm.nih.gov/pubmed/29352318
http://dx.doi.org/10.1371/journal.pone.0191511

Ejemplares similares